Tolerability of Nintedanib (BIBF 1120) in Combination with Docetaxel: A Phase 1 Study in Japanese Patients with Previously Treated Non–Small-Cell Lung Cancer期刊界 All Journals 搜尽天下杂志传播学术成果专业期刊搜索期刊信息化学术搜索

按检索

Tolerability of Nintedanib (BIBF 1120) in Combination with Docetaxel: A Phase 1 Study in Japanese Patients with Previously Treated Non–Small-Cell Lung Cancer

Institution:	2. Center for Clinical and Translational Research, Faculty of Medicine, Kyusyu University Hospital, Fukuoka, Japan;3. Department of Internal Medicine, Suita Municipal Hospital, Osaka, Japan;4. Department of Medical Oncology, Nara Hospital, Kinki University Faculty of Medicine, Nara, Japan;5. Department of Medical Oncology, Kishiwada Municipal Hospital, Osaka, Japan;11. Department of Medical Oncology, National Kyushu Cancer Centre, Fukuoka, Japan;12. Nippon Boehringer Ingelheim Co. Ltd., Medical Development Division, Hyogo, Japan;8. Clinical Pharmacokinetics/Pharmacodynamics Department, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany

Abstract:

Keywords:	Clinical trials Phase I Docetaxel Japanese Nintedanib Non–small-cell lung cancer Pharmacokinetics
本文献已被 ScienceDirect 等数据库收录！